Global Heart Failure Academy: Recent Episodes
ReachMD
Leading global experts have combined guideline recommendations and new clinical data with practical, case-based formats that approximate clinical reality to improve patient outcomes in the management of heart failure. This series is focused on changing clinical behavior in the recognition and diagnoses of hyperkalemia and iron deficiency in heart failure, through the application of emerging science into everyday practice. To return to the Global Heart Failure Academy, please click here. This educational series is developed by Medtelligence. Supported by an unrestricted educational grant from CSL Vifor.
Host: Mikhail Kosiborod, MD
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with CKD or heart failure face the risk of developing hyperkalemia, and healthcare providers often experience clinical inertia in their treatment. Join the experts as they explore chronic hyperkalemia management, and the role of potassium binders.
Guest: David Wheeler, MB, CHB, MD, FRCP
Hyperkalemia is a common complication in patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy. Join Dr. David Wheeler as he explores strategies for managing hyperkalemia while optimizing treatment benefits. Learn about patient-centered communication techniques, risk factors, and treatment options. Discover the importance of ongoing monitoring and follow-up to ensure optimal management. You don’t want to miss this opportunity to improve your clinical practice and enhance patient outcomes.
Host: Stefan D. Anker, MD, PhD
Guest: John Cleland, MD
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is a common heart failure comorbidity with a negative impact on patients’ quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions?
Host: George L. Bakris, MD, FAHA, FASN
Guest: David Bushinsky, MD
Guest: Lars Lund, MD
Hyperkalemia is a limiting factor when treating patients with heart failure and CKD on RAASi therapy. It’s especially challenging when these patients are on chronic hemodialysis. Join Drs. George Bakris, David Bushinsky, and Lars Lund as they identify the barriers of optimal treatment in patients on hemodialysis and discuss the real-world evidence using potassium-lowering agents in challenging patient group.
Host: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Iron deficiency is an independent predictor of decreased functional capacity and reduced survival in our patients with heart failure. Multiple clinical trials have addressed the issue, but we continue to struggle with the clinical implications of the data. Join Drs. Stefan Anker, Robert Mentz, and Piotr Ponikowski as they discuss the evidence from IV iron trials in heart failure, past and present, and what the results mean for your practice and patients.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Marco Metra, MD
Guest: Gianluigi Savarese, MD
Clinical trials provide evidence to support guideline recommendations. What’s changed with the recommendations for iron deficiency in heart failure? Watch as experts Giuseppe Rosano, MD, Marco Metra, MD, and Gianluigi Savarese, MD discuss the recent updates to the ESC guidelines, including the latest clinical trial evidence, and the expanded use of IV iron in iron deficient heart failure patients.
Host: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Patrick Rossignol, MD, PhD
Heart failure and chronic kidney disease can go hand in hand in your patients, and when they do, there are often added comorbidities such as diabetes. If your patients on RAASi therapy develop hyperkalemia, what should you do? Join Drs. Patrick Rossignol and Antoni Bayés-Genís as they consult on a patient with heart failure who has multiple comorbidities and discuss the impact of hyperkalemia in these complex patients.
Host: Ellie Kelepouris, MD, FACP, FAHA
Guest: Stephen J. Greene, MD, FACC, FHFSA
Patients with heart failure and chronic kidney disease (CKD) are challenging to manage. The best approach is a multidisciplinary one, which will help to optimize guideline-directed medical therapy in patients at risk for hyperkalemia. Join Drs. Ellie Kelepouris and Stephen Greene as they discuss how to identify patients at high risk of developing hyperkalemia and the available treatment strategies for these complex patients.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Antoni Bayés-Genís, MD, PhD, FESC, FHFA
Guest: Ovidiu Chioncel, MD, PhD
Guest: Marco Metra, MD
Experts agree intravenous iron treatment for iron-deficient patients with heart failure can improve outcomes, but what are we learning from the recent clinical trials? Drs. Giuseppe Rosano, Marco Metra, Ovidiu Chioncel, and Antoni Bayés-Genís highlight the latest data as they discuss the recent updates to the ESC guidelines and provide expert analysis regarding clinical trials using IV iron. Discover the clinical relevance of the evidence from these trials in patients with heart failure and iron deficiency.
Host: Piotr Ponikowski, MD, PhD, FESC, FHFA
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few have addressed the long-term effects of IV iron treatment on morbidity, mortality, and exercise tolerance in these patients. Join Dr. Robert Mentz and Dr. Piotr Ponikowski as they discuss the design of the HEART-FID trial and its potential impact on the clinical applications of long-term treatment with IV iron products in patients with heart failure and iron deficiency.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Patrick Rossignol, MD, PhD
With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Piña, MD, and faculty members cardiologist Javed Butler, MD, and nephrologist Patrick Rossignol, MD, use case-based vignettes to provide expert analysis regarding hyperkalemia in patients with HFrEF who are on RAASi therapy. Tune in for insights on applying clinical trial data to the unique challenges of complex cases and learn how a guideline-based approach, innovative treatments, and emerging data are achieving successful outcomes in patients with heart failure with hyperkalemia.
Host: Javed Butler, MD, MBA, MPH
Guest: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even though it is well known that suboptimal use of these therapies leads to poorer outcomes for our patients with heart failure and chronic kidney disease. Join Drs. Javed Butler, Ileana Piña, and Patrick Rossignol as they take a multidisciplinary approach to a patient case and discuss dosing and other treatment decisions.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Piotr Ponikowski, MD, PhD, FESC, FHFA
Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.
Host: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Kamyar Kalantar‐Zadeh, MD
Guest: Pieter Martens, MD, PhD
Patients with heart failure are at increased risk for iron deficiency which leads to poor outcomes and quality of life. Several intravenous iron formulations are available to clinicians, yet iron deficiency remains undertreated. Join Dr. Giuseppe Rosano, Dr. Pieter Martens, and Dr. Kamyar Kalantar-Zadeh as they discuss differing iron formulations and the current body of evidence for managing iron deficiency in patients with heart failure.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency in patients with heart failure remains underdiagnosed, undertreated, and commonly overlooked in non-anemic patients and has a significant impact on patient outcomes and quality of life. Join Dr. Robert Mentz and Dr. Peter van der Meer as they discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Patrick Rossignol, MD, PhD
In heart failure, the use of MRAs is often delayed despite being a crucial part of medical therapy. The evidence is clear that clinical inertia and the suboptimal use of these therapies leads to poorer outcomes for our patients. Join Dr. Ileana Piña and Dr. Patrick Rossignol as they discuss approaches to the clinical stigma surrounding the use of MRAs, as well as management strategies to better ensure the best medical therapy possible for our patients with heart failure.
Host: Marco Metra, MD
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
Iron deficiency, independent of anemia status, is common in heart failure and is associated with increased risk for heart failure hospitalization and cardiovascular mortality, reduced functional status, and poor exercise performance. This impact may be magnified in patients with ischemic etiology. Join Dr. Marco Metra and Dr. Piotr Ponikowski as they discuss the clinical relevance of ischemic etiology in the management and outcomes of patients with heart failure and iron deficiency.
Host: Mikhail Kosiborod, MD
Optimizing GDMT for patients with heart failure and concomitant kidney dysfunction and/or diabetes continues to be a challenge despite the overwhelming clinical evidence and recent updates to the guidelines for heart failure management. Recent evidence from clinical trials with SGLT2 inhibitors and mineralocorticoid receptor antagonists and the use of novel potassium binders provide new therapeutic opportunities for these patients. This activity will review the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes.
Host: Mikhail Kosiborod, MD
Guest: Michael Böhm, MD, FESC
The 2022 updates to the ACC/AHA guidelines for heart failure are the first since 2017. In the interim, considerable research has been conducted on the impact of optimal RAASi therapy and the management of hyperkalemia in patients with heart failure. Join Dr. Mikhail Kosiborod and Dr. Michael Böhm as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Marco Metra, MD
Guest: Adrian F. Hernandez, MD, MHS
Since the 2017 AHA/ACC/HFSA guidelines, considerable research has been conducted in the care of patients with heart failure, including the impact of iron deficiency. The new 2022 guidelines have considerable updates based on the totality of current evidence. Join Dr. Adrian Hernandez and Dr. Marco Metra as they discuss key highlights from the guidelines and make sure you’re staying up to date with the evolving data and best practices.
Host: Mikhail Kosiborod, MD
Guest: Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI
RAASi therapy is a critical component of heart failure management; however, concern about patients developing hyperkalemia often leads to clinical delay and suboptimal dosing. This is especially evident in our patients with chronic kidney disease. So how can we simultaneously maintain optimal therapy and manage hyperkalemia? Join Dr. Mikhail Kosiborod and Dr. Austin Stack as they discuss a patient case and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Javed Butler, MD, MBA, MPH
Guest: Stefan D. Anker, MD, PhD
The DIAMOND trial recently released topline results, adding to the growing clinical evidence for the use of potassium binders in the management of hyperkalemia in patients with heart failure. So what do the data mean for our patients? Join Dr. Stefan Anker and Dr. Javed Butler as they discuss the value of these results and make sure you’re staying up to date with the evolving data, guidelines, and practices.
Host: Peter van der Meer, MD, PhD
Guest: Pieter Martens, MD, PhD
Iron deficiency (ID), independent of anemia status, is common in heart failure with reduced ejection fraction (HFrEF). In normal cardiac physiology, contractility increases disproportionally to heart rate; however, in HFrEF and concomitant ID, this response is impaired. Additionally, HFrEF patients with ID who receive cardiac resynchronization therapy (CRT) exhibit diminished cardiac reverse remodeling after CRT implant.
In this discussion, Drs. Martens and van der Meer discuss how physicians can work to improve reverse cardiac remodeling, the force-frequency relationship, and quality of life in patients with HFrEF and ID receiving CRT.
Host: George L. Bakris, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Hyperkalemia is common in chronic heart failure and is associated with an increased risk of hospitalization and death. The incidence is further elevated in those with chronic kidney disease, and the presence of hyperkalemia can often lead to clinical delay and suboptimal dosing of RAAS inhibitors in these patients.
Join the discussion as Drs. George Bakris and Giuseppe Rosano examine the management of hyperkalemia in patients with HF and provide individualized approaches for optimizing RAASi therapy. Collaboration between nephrologists and cardiologists is key, and these experts make sure to stress the strong connection between the heart and kidneys when managing these patients.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Marco Metra, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.
Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.
Host: Javed Butler, MD, MBA, MPH
Guest: Piotr Ponikowski, MD, PHD, FESC, FHFA
In this video, Drs. Javed Butler and Piotr Ponikowski discuss the clinical significance of iron deficiency in patients suffering from heart failure with reduced ejection fraction. They also take a close look at the key updates to the 2021 ESC/HFA guidelines. Tune in to stay up to date with the latest recommendations.
Host: Gregg C. Fonarow, MD
Guest: Andrew J. S. Coats, MD
Rapid initiation and up-titration of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy is critical in the management of heart failure, especially given the prevalence of comorbid conditions, such as recurrent hyperkalemia, in these patients. To improve patient outcomes, it is crucial that physicians avoid any unnecessary halting or dose reductions to these medications.
In this discussion, Drs. Coats and Fonarow review updates to the ESC/HFA guidelines and explain how these changes affect patient care. Find out how to maintain optimal RAASi therapy for your patients with heart failure in the face of their challenging comorbidities.
Host: Keith C. Ferdinand, MD
Guest: Marco Metra, MD
There is a substantial gap between the guideline recommendations for treatment and the real-world prescribing patterns of RAASi therapy. This disconnect results in worse cardiorenal outcomes and higher mortality in patients receiving suboptimal dosing. This is particularly true in patients with CKD who develop hyperkalemia, which constitutes the major barrier to optimal therapy.
In this activity, Drs. Ferdinand and Metra discuss how best to manage comorbidities, optimize RAASi therapy, and improve the long-term care for our patients with heart failure.
Host: Mikhail Kosiborod, MD
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Phil McEwan, PhD
Assessing iron deficiency is a crucial aspect of heart failure (HF) that warrants close clinical consideration, especially because it remains underdiagnosed and undertreated.
In this expert panel discussion, we examine data from AFFIRM-HF supporting the importance of correcting iron deficiency in patients with HF. Find out how treating iron deficiency can change the natural history of heart disease, lead to cost savings, and improve patients’ lives.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Rapid initiation and up-titration of guideline-directed medical therapy (GDMT) is critical to achieve optimal patient outcomes in heart failure. This is particularly important in patients with multiple comorbidities and in pivotal situations to avoid stopping or lowering the dose of any of the four critical medicines that these patients must receive.
Drs. Javed Butler, Ileana Piña, and Giuseppe Rosano will recap the data and the views that were presented at a symposium held in conjunction with the Heart Failure Society of America’s 2021 annual scientific meeting.
Host: Ileana L. Piña, MD, MPH, FAHA, FACC
Guest: Javed Butler, MD, MBA, MPH
Guest: Gregg C. Fonarow, MD
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Recent guideline updates and publications are leading to changes in care in patients with heart failure with reduced ejection fraction (HFrEF). What clinical evidence is driving recent changes to guideline directed medical therapy (GDMT) in HFrEF, and what real-world data exists that may impact the landscape of care and patient outcomes?
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
The COVID-19 pandemic has had an unprecedented impact on the entire global population. COVID-19 fears have not only disrupted the regular care of patients with heart failure, but also clinical trials and their participation rates.
These studies are critical for determining the safety and efficacy of new drugs and innovative treatments. When the pandemic started, some clinical trials shut down permanently while others are finally, albeit slowly, resuming. This has created a delay in the research pipeline that may hinder how quickly new heart failure medications come to market in the next few years.
Join us as our experts—Drs. Deepak Bhatt, Javed Butler, and Giuseppe Rosano—discuss the impact of COVID-19 on patient care and the implications for clinical trial data moving forward.
Host: Robert J. Mentz, MD, FHFSA, FACC, FAHA
Guest: Peter van der Meer, MD, PhD
Iron deficiency is an extremely common comorbidity for 50% to 70% of our patients with heart failure in both the acute and chronic settings. It’s associated with poor exercise capacity, poor quality of life, and increased morbidity and mortality. In hospitalized patients with acute heart failure, iron deficiency is often present independent of anemia.
With that in mind, join Drs. Robert Mentz and Peter van der Meer as they discuss the impact of iron deficiency on patients with heart failure. Find out why it’s time to shift our perception of iron deficiency from a marker of disease outcome to a treatment target.
Host: Javed Butler, MD, MBA, MPH
Guest: Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
It is well understood that RAASi therapy is critical in the management of patients with heart failure. However, hyperkalemia is common in these patients, and its presence often leads to suboptimal RAASi dosing, which in turn results in poorer patient outcomes. Join Drs. Javed Butler and Giuseppe Rosano as they look at a case presentation and discuss the hows and whys of optimal RAASi dosing in patients with heart failure and recurrent hyperkalemia.
Host: Ewa A. Jankowska, MD, PhD, FESC
Hospitalizations due to acute heart failure represent a growing healthcare problem and a large economic burden. Iron deficiency, irrespective of anemia, is prevalent among this population and is associated with a high risk for increased mortality and rehospitalization. Tune in to discover the latest data from the AFFIRM-AHF trial. What does this new information reveal about treatment with intravenous iron in patients with acute heart failure?
Host: Stefan D. Anker, MD, PhD
Guest: Javed Butler, MD, MBA, MPH
Guest: Ewa A. Jankowska, MD, PhD, FESC
Guest: Josep Comin-Colet, MD, PhD
How does treatment of iron deficiency affect outcomes in patients hospitalized for acute decompensated heart failure? This late-breaking video brief reviews the topline results of the AFFIRM-AHF data released at the 2020 American Heart Association Scientific Sessions and provides reactions from several heart failure experts on what these data mean on a global level.
Host: Mikhail Kosiborod, MD
Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world data surrounding this question and its associated impact on outcomes.